Answer
Lazertinib inhibits the BCRP transporter, and co-administration with 160 mg lazertinib increased rosuvastatin plasma exposure approximately twofold, with Cmax and AUC geometric mean ratios of 2.24 and 2.02, respectively, versus rosuvastatin alone.
Sources for this answer
- Lazcluze 80 mg film-coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.5 Interaction with other medicinal products · Version 3Document updated
Sources checked